Supriya Lifescience Eyes 33-35% Ebitda Margins In FY26 Led By New Products, US Expansion

Supriya Lifescience, a leading player in the active pharmaceutical ingredients (API) and contract development and manufacturing organisation (CDMO) segments, is confident of achieving Ebitda margins of 33-35% in FY26, according to the company’s Executive Chairman Satish Waman Wagh. He outlined a multi-pronged strategy focused on new product launches, capacity expansion, challenging Chinese players in the international market and a strategic foray into the high-margin US market.